The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC

ABSTRACT: Gemcitabine is considered a standard treatment for pancreatic cancer, but developing drug resistance greatly limits the effectiveness of chemotherapy and increases the rate of recurrence. Lysyl oxide-like 2 (LOXL2) is highly expressed in pancreatic cancer and is involved in carcinogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yun Sun, Kim, Hyung Sun, Kim, Hyo Jung, Kang, Hyeon Woong, Lee, Da Eun, Kim, Myeong Jin, Hong, Woosol Chris, Kim, Ju Hyun, Kim, Minsoo, Cheong, Jae-Ho, Park, Joon Seong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663195/
https://www.ncbi.nlm.nih.gov/pubmed/37737908
http://dx.doi.org/10.1007/s00109-023-02369-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663195/
https://www.ncbi.nlm.nih.gov/pubmed/37737908
http://dx.doi.org/10.1007/s00109-023-02369-6

Ejemplares similares